View ValuationMabion 将来の成長Future 基準チェック /06現在、 Mabionの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • Dec 10Consensus revenue estimates decrease by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from zł87.1m to zł66.1m. EPS estimate unchanged from -zł0.28 per share at last update. Biotechs industry in Poland expected to see average net income growth of 26% next year. Consensus price target down from zł11.50 to zł8.17. Share price fell 9.1% to zł10.56 over the past week.Price Target Changed • Nov 27Price target decreased by 13% to zł13.83Down from zł15.83, the current price target is an average from 3 analysts. New target price is 14% above last closing price of zł12.14. Stock is down 41% over the past year. The company posted earnings per share of zł2.55 last year.Price Target Changed • Apr 19Price target increased by 9.6% to zł16.17Up from zł14.75, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of zł17.00. Stock is down 9.0% over the past year. The company posted earnings per share of zł2.55 last year.Major Estimate Revision • May 28Consensus revenue estimates decrease by 17%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from zł190.5m to zł159.0m. EPS estimate increased from zł0.52 to zł2.07 per share. Net income forecast to grow 42% next year vs 18% growth forecast for Biotechs industry in Poland. Consensus price target up from zł14.75 to zł15.35. Share price was steady at zł18.10 over the past week.Price Target Changed • Apr 19Price target decreased by 9.2% to zł14.75Down from zł16.25, the current price target is an average from 2 analysts. New target price is 22% below last closing price of zł18.90. Stock is down 44% over the past year. The company is forecast to post earnings per share of zł1.57 for next year compared to zł0.12 last year.Major Estimate Revision • Dec 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from zł183.9m to zł164.9m. EPS estimate unchanged from zł1.57 per share at last update. Biotechs industry in Poland expected to see average net income growth of 1.6% next year. Consensus price target down from zł16.25 to zł15.75. Share price rose 5.1% to zł22.04 over the past week.すべての更新を表示Recent updatesReported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.New Risk • May 05New major risk - Revenue and earnings growthEarnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł42m free cash flow). Earnings have declined by 3.5% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł119.6m market cap, or US$32.9m).Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.67 loss per share (vs zł1.01 loss in 3Q 2024)Third quarter 2025 results: zł0.67 loss per share (improved from zł1.01 loss in 3Q 2024). Revenue: zł4.08m (up zł3.57m from 3Q 2024). Net loss: zł10.8m (loss narrowed 34% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.95 loss per share (vs zł0.64 profit in 2Q 2024)Second quarter 2025 results: zł0.95 loss per share (down from zł0.64 profit in 2Q 2024). Revenue: zł3.26m (down 89% from 2Q 2024). Net loss: zł15.4m (down 250% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.お知らせ • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025New Risk • Jun 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: zł39m Forecast net loss in 1 year: zł33m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (zł33m net loss next year). Market cap is less than US$100m (zł155.8m market cap, or US$41.4m).Reported Earnings • May 29First quarter 2025 earnings released: zł0.94 loss per share (vs zł1.09 profit in 1Q 2024)First quarter 2025 results: zł0.94 loss per share (down from zł1.09 profit in 1Q 2024). Revenue: zł2.72m (down 92% from 1Q 2024). Net loss: zł15.3m (down 187% from profit in 1Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł11.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 60% over the past three years.お知らせ • Apr 25Mabion S.A., Annual General Meeting, May 26, 2025Mabion S.A., Annual General Meeting, May 26, 2025.分析記事 • Apr 15Mabion S.A.'s (WSE:MAB) Revenues Are Not Doing Enough For Some InvestorsMabion S.A.'s ( WSE:MAB ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right now...分析記事 • Dec 22Revenues Working Against Mabion S.A.'s (WSE:MAB) Share Price Following 29% DiveTo the annoyance of some shareholders, Mabion S.A. ( WSE:MAB ) shares are down a considerable 29% in the last month...Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł8.56, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total loss to shareholders of 86% over the past three years.Major Estimate Revision • Dec 10Consensus revenue estimates decrease by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from zł87.1m to zł66.1m. EPS estimate unchanged from -zł0.28 per share at last update. Biotechs industry in Poland expected to see average net income growth of 26% next year. Consensus price target down from zł11.50 to zł8.17. Share price fell 9.1% to zł10.56 over the past week.Price Target Changed • Nov 27Price target decreased by 13% to zł13.83Down from zł15.83, the current price target is an average from 3 analysts. New target price is 14% above last closing price of zł12.14. Stock is down 41% over the past year. The company posted earnings per share of zł2.55 last year.Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 23%After last week's 23% share price gain to zł12.54, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past three years.分析記事 • Nov 06Some May Be Optimistic About Mabion's (WSE:MAB) EarningsThe most recent earnings report from Mabion S.A. ( WSE:MAB ) was disappointing for shareholders. While the headline...New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 117% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.2% net profit margin). Market cap is less than US$100m (zł184.3m market cap, or US$46.0m).分析記事 • Nov 05Investors Don't See Light At End Of Mabion S.A.'s (WSE:MAB) Tunnel And Push Stock Down 30%Mabion S.A. ( WSE:MAB ) shareholders that were waiting for something to happen have been dealt a blow with a 30% share...Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (zł307.1m market cap, or US$79.2m).New Risk • Jul 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (zł283.8m market cap, or US$72.4m).お知らせ • May 25Mabion S.A., Annual General Meeting, Jun 17, 2024Mabion S.A., Annual General Meeting, Jun 17, 2024.Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.分析記事 • Apr 24Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory ProfitFollowing the solid earnings report from Mabion S.A. ( WSE:MAB ), the market responded by bidding up the stock price...Price Target Changed • Apr 19Price target increased by 9.6% to zł16.17Up from zł14.75, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of zł17.00. Stock is down 9.0% over the past year. The company posted earnings per share of zł2.55 last year.Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 16% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (zł277.2m market cap, or US$68.7m).お知らせ • Jan 12+ 3 more updatesMabion S.A. to Report Q3, 2024 Results on Nov 25, 2024Mabion S.A. announced that they will report Q3, 2024 results on Nov 25, 2024分析記事 • Nov 28Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For GrowthThe Mabion S.A. ( WSE:MAB ) share price has done very well over the last month, posting an excellent gain of 30%. While...Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 22%After last week's 22% share price gain to zł21.88, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 1.8% over the past three years.Reported Earnings • Nov 17Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł29.6m (down 23% from 3Q 2022). Net income: zł10.9m (up zł15.9m from 3Q 2022). Profit margin: 37% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe.お知らせ • Jun 13Mabion S.A., Annual General Meeting, Jun 13, 2023Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time.分析記事 • Jun 02Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue ForecastsMabion S.A. ( WSE:MAB ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...Major Estimate Revision • May 28Consensus revenue estimates decrease by 17%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from zł190.5m to zł159.0m. EPS estimate increased from zł0.52 to zł2.07 per share. Net income forecast to grow 42% next year vs 18% growth forecast for Biotechs industry in Poland. Consensus price target up from zł14.75 to zł15.35. Share price was steady at zł18.10 over the past week.Price Target Changed • Apr 19Price target decreased by 9.2% to zł14.75Down from zł16.25, the current price target is an average from 2 analysts. New target price is 22% below last closing price of zł18.90. Stock is down 44% over the past year. The company is forecast to post earnings per share of zł1.57 for next year compared to zł0.12 last year.お知らせ • Jan 26+ 2 more updatesMabion S.A. to Report First Half, 2023 Results on Sep 12, 2023Mabion S.A. announced that they will report first half, 2023 results on Sep 12, 2023Major Estimate Revision • Dec 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from zł183.9m to zł164.9m. EPS estimate unchanged from zł1.57 per share at last update. Biotechs industry in Poland expected to see average net income growth of 1.6% next year. Consensus price target down from zł16.25 to zł15.75. Share price rose 5.1% to zł22.04 over the past week.Price Target Changed • Nov 16Price target decreased to zł16.25Down from zł26.00, the current price target is an average from 2 analysts. New target price is 26% below last closing price of zł22.00. Stock is down 67% over the past year. The company is forecast to post earnings per share of zł1.57 for next year compared to zł0.12 last year.Major Estimate Revision • Oct 06Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from zł275.0m to zł183.9m. EPS estimate unchanged from zł1.57 per share at last update. Biotechs industry in Poland expected to see average net income growth of 8.6% next year. Consensus price target down from zł26.00 to zł16.25. Share price was steady at zł19.86 over the past week.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł26.18, the stock trades at a trailing P/E ratio of 16x. Average forward P/E is 22x in the Biotechs industry in Poland. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at zł12.27 per share.分析記事 • Jul 09Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł25.20, the stock trades at a trailing P/E ratio of 15.4x. Average forward P/E is 32x in the Biotechs industry in Poland. Total loss to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at zł11.29 per share.Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to zł21.60, the stock trades at a trailing P/E ratio of 13.2x. Average forward P/E is 31x in the Biotechs industry in Poland. Total loss to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at zł11.53 per share.分析記事 • Jun 04Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good NewsSolid profit numbers didn't seem to be enough to please Mabion S.A.'s ( WSE:MAB ) shareholders. We think that they...Price Target Changed • Apr 27Price target increased to zł68.50Up from zł47.30, the current price target is provided by 1 analyst. New target price is 145% above last closing price of zł28.00. Stock is down 57% over the past year. The company is forecast to post a net loss per share of zł3.67 next year compared to a net loss per share of zł4.06 last year.Breakeven Date Change • Apr 27Forecast breakeven date moved forward to 2022The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Buying Opportunity • Jan 24Now 33% undervalued after recent price dropOver the last 90 days, the stock is down 45%. The fair value is estimated to be zł59.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 157% per annum over the last 3 years. Earnings per share has grown by 16% per annum over the last 3 years.分析記事 • Dec 22Is Mabion (WSE:MAB) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Price Target Changed • Oct 12Price target increased to zł68.50Up from zł47.50, the current price target is an average from 2 analysts. New target price is 13% below last closing price of zł78.90. Stock is up 186% over the past year.分析記事 • Sep 11Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value EstimateToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Mabion S.A. ( WSE:MAB...Major Estimate Revision • Jul 25Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from zł8.00m to zł51.5m. EPS estimate unchanged from -zł3.67 at last update. Biotechs industry in Poland expected to see average net income decline 11% next year. Consensus price target up from zł27.30 to zł47.50. Share price rose 11% to zł64.00 over the past week.お知らせ • Mar 04Mabion Biotech Signs Deal with Novavax on Covid-19 Vaccine Technology TransferMabion signed a deal with Novavax to transfer the manufacturing process and open the way for commercial-scale production of an antigen for a COVID-19 vaccine candidate, Mabion. The Master Service Agreement enables Mabion "with assistance of Novavax, to initiate activities required to transfer the manufacturing process and to establish the feasibility of commercial-scale manufacturing of antigen for Novavax's vaccine candidate" at Mabion's premises. Mabion expects that the transfer of the technology and its verification will be completed in first half 2021. The deal is effective through December 31, 2023.分析記事 • Feb 24How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?The big shareholder groups in Mabion S.A. ( WSE:MAB ) have power over the company. Institutions often own shares in...Is New 90 Day High Low • Feb 22New 90-day high: zł27.40The company is up 13% from its price of zł24.20 on 24 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł7.76 per share.お知らせ • Jan 08+ 3 more updatesMabion S.A. to Report Q2, 2021 Results on Sep 16, 2021Mabion S.A. announced that they will report Q2, 2021 results on Sep 16, 2021Is New 90 Day High Low • Dec 21New 90-day low: zł20.50The company is down 34% from its price of zł31.20 on 22 September 2020. The Polish market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.Is New 90 Day High Low • Nov 30New 90-day low: zł21.50The company is down 33% from its price of zł32.25 on 01 September 2020. The Polish market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 12% over the same period.Is New 90 Day High Low • Oct 30New 90-day low: zł21.90The company is down 11% from its price of zł24.50 on 31 July 2020. The Polish market is down 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 11% over the same period.お知らせ • Jun 16Mabion S.A. announced that it expects to receive PLN 1.563755 million in fundingMabion S.A. (WSE:MAB) announced a private placement of up to 1,907,281 ordinary U series bearer shares for minimum gross proceeds of PLN 190,728.10 and maximum of PLN 1,563,755.30 in May 2020. The transaction will include participation from new shareholders, as the shares issued will be in accordance of the exclusion of pre-emptive rights for existing shareholders. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Mabion は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測WSE:MAB - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202516-63-42-42N/A9/30/202515-59-41-40N/A6/30/202511-65-38-37N/A3/31/202538-39-22N/A12/31/202469-62840N/A9/30/2024111101547N/A6/30/2024140371255N/A3/31/202414642-414N/A12/31/202315241-40-2N/A9/30/2023148583462N/A6/30/2023157423352N/A3/31/2023165326984N/A12/31/2022164232239N/A9/30/202215645-67-46N/A6/30/202211734-52-24N/A3/31/20227526-109-75N/A12/31/2021362-65-33N/A9/30/20212-51-38-20N/A6/30/20212-45-58-49N/A3/31/2021N/A-53-13-10N/A12/31/2020N/A-56-39-35N/A9/30/2020N/A-55-40-35N/A6/30/2020N/A-63-35-30N/A3/31/2020N/A-69-37-31N/A12/31/2019N/A-64-43-34N/A9/30/2019N/A-65N/A-31N/A6/30/2019N/A-59N/A-24N/A3/31/2019N/A-70N/A-34N/A12/31/2018N/A-69N/A-39N/A9/30/2018N/A-72N/A-42N/A6/30/2018N/A-74N/A-62N/A3/31/2018N/A-59N/A-61N/A12/31/2017N/A-58N/A-54N/A9/30/2017N/A-56N/A-35N/A6/30/2017N/A-57N/A-24N/A3/31/2017N/A-59N/A-26N/A12/31/2016N/A-56N/A-15N/A9/30/20160-77N/A-36N/A6/30/20160-65N/A-44N/A3/31/20163-51N/A-30N/A12/31/20153-43N/A-32N/A9/30/20153-6N/A-29N/A6/30/20153-5N/A-24N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MABの予測収益成長が 貯蓄率 ( 5.3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MABの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MABの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MABの収益がPolish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MABの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MABの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 12:27終値2026/05/25 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mabion S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Beata Szparaga-WasniewskaBiuro maklerskie mBankuKamil KliszczBiuro maklerskie mBankuPawel PuchalskiErste Bank Polska S.A.4 その他のアナリストを表示
Major Estimate Revision • Dec 10Consensus revenue estimates decrease by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from zł87.1m to zł66.1m. EPS estimate unchanged from -zł0.28 per share at last update. Biotechs industry in Poland expected to see average net income growth of 26% next year. Consensus price target down from zł11.50 to zł8.17. Share price fell 9.1% to zł10.56 over the past week.
Price Target Changed • Nov 27Price target decreased by 13% to zł13.83Down from zł15.83, the current price target is an average from 3 analysts. New target price is 14% above last closing price of zł12.14. Stock is down 41% over the past year. The company posted earnings per share of zł2.55 last year.
Price Target Changed • Apr 19Price target increased by 9.6% to zł16.17Up from zł14.75, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of zł17.00. Stock is down 9.0% over the past year. The company posted earnings per share of zł2.55 last year.
Major Estimate Revision • May 28Consensus revenue estimates decrease by 17%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from zł190.5m to zł159.0m. EPS estimate increased from zł0.52 to zł2.07 per share. Net income forecast to grow 42% next year vs 18% growth forecast for Biotechs industry in Poland. Consensus price target up from zł14.75 to zł15.35. Share price was steady at zł18.10 over the past week.
Price Target Changed • Apr 19Price target decreased by 9.2% to zł14.75Down from zł16.25, the current price target is an average from 2 analysts. New target price is 22% below last closing price of zł18.90. Stock is down 44% over the past year. The company is forecast to post earnings per share of zł1.57 for next year compared to zł0.12 last year.
Major Estimate Revision • Dec 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from zł183.9m to zł164.9m. EPS estimate unchanged from zł1.57 per share at last update. Biotechs industry in Poland expected to see average net income growth of 1.6% next year. Consensus price target down from zł16.25 to zł15.75. Share price rose 5.1% to zł22.04 over the past week.
Reported Earnings • May 24First quarter 2026 earnings released: zł0.60 loss per share (vs zł0.94 loss in 1Q 2025)First quarter 2026 results: zł0.60 loss per share (improved from zł0.94 loss in 1Q 2025). Revenue: zł4.57m (up 68% from 1Q 2025). Net loss: zł9.74m (loss narrowed 36% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
New Risk • May 05New major risk - Revenue and earnings growthEarnings have declined by 3.5% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł42m free cash flow). Earnings have declined by 3.5% per year over the past 5 years. Minor Risks Revenue is less than US$5m (zł16m revenue, or US$4.3m). Market cap is less than US$100m (zł119.6m market cap, or US$32.9m).
Reported Earnings • Dec 03Third quarter 2025 earnings released: zł0.67 loss per share (vs zł1.01 loss in 3Q 2024)Third quarter 2025 results: zł0.67 loss per share (improved from zł1.01 loss in 3Q 2024). Revenue: zł4.08m (up zł3.57m from 3Q 2024). Net loss: zł10.8m (loss narrowed 34% from 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.95 loss per share (vs zł0.64 profit in 2Q 2024)Second quarter 2025 results: zł0.95 loss per share (down from zł0.64 profit in 2Q 2024). Revenue: zł3.26m (down 89% from 2Q 2024). Net loss: zł15.4m (down 250% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
お知らせ • Aug 25Mabion S.A. to Report First Half, 2025 Results on Sep 30, 2025Mabion S.A. announced that they will report first half, 2025 results on Sep 30, 2025
New Risk • Jun 08New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: zł39m Forecast net loss in 1 year: zł33m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (zł33m net loss next year). Market cap is less than US$100m (zł155.8m market cap, or US$41.4m).
Reported Earnings • May 29First quarter 2025 earnings released: zł0.94 loss per share (vs zł1.09 profit in 1Q 2024)First quarter 2025 results: zł0.94 loss per share (down from zł1.09 profit in 1Q 2024). Revenue: zł2.72m (down 92% from 1Q 2024). Net loss: zł15.3m (down 187% from profit in 1Q 2024). Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to zł11.50, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 26x in the Biotechs industry in Europe. Total loss to shareholders of 60% over the past three years.
お知らせ • Apr 25Mabion S.A., Annual General Meeting, May 26, 2025Mabion S.A., Annual General Meeting, May 26, 2025.
分析記事 • Apr 15Mabion S.A.'s (WSE:MAB) Revenues Are Not Doing Enough For Some InvestorsMabion S.A.'s ( WSE:MAB ) price-to-sales (or "P/S") ratio of 1.5x might make it look like a strong buy right now...
分析記事 • Dec 22Revenues Working Against Mabion S.A.'s (WSE:MAB) Share Price Following 29% DiveTo the annoyance of some shareholders, Mabion S.A. ( WSE:MAB ) shares are down a considerable 29% in the last month...
Valuation Update With 7 Day Price Move • Dec 20Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to zł8.56, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 28x in the Biotechs industry in Europe. Total loss to shareholders of 86% over the past three years.
Major Estimate Revision • Dec 10Consensus revenue estimates decrease by 24%The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from zł87.1m to zł66.1m. EPS estimate unchanged from -zł0.28 per share at last update. Biotechs industry in Poland expected to see average net income growth of 26% next year. Consensus price target down from zł11.50 to zł8.17. Share price fell 9.1% to zł10.56 over the past week.
Price Target Changed • Nov 27Price target decreased by 13% to zł13.83Down from zł15.83, the current price target is an average from 3 analysts. New target price is 14% above last closing price of zł12.14. Stock is down 41% over the past year. The company posted earnings per share of zł2.55 last year.
Valuation Update With 7 Day Price Move • Nov 26Investor sentiment improves as stock rises 23%After last week's 23% share price gain to zł12.54, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total loss to shareholders of 83% over the past three years.
分析記事 • Nov 06Some May Be Optimistic About Mabion's (WSE:MAB) EarningsThe most recent earnings report from Mabion S.A. ( WSE:MAB ) was disappointing for shareholders. While the headline...
New Risk • Nov 06New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 117% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (9.2% net profit margin). Market cap is less than US$100m (zł184.3m market cap, or US$46.0m).
分析記事 • Nov 05Investors Don't See Light At End Of Mabion S.A.'s (WSE:MAB) Tunnel And Push Stock Down 30%Mabion S.A. ( WSE:MAB ) shareholders that were waiting for something to happen have been dealt a blow with a 30% share...
Reported Earnings • Oct 29Third quarter 2024 earnings released: zł1.01 loss per share (vs zł0.67 profit in 3Q 2023)Third quarter 2024 results: zł1.01 loss per share (down from zł0.67 profit in 3Q 2023). Revenue: zł516.0k (down 98% from 3Q 2023). Net loss: zł16.3m (down 250% from profit in 3Q 2023). Revenue is expected to decline by 11% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 21%. Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has fallen by 44% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 11Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: zł29.8m (down 17% from 2Q 2023). Net income: zł10.3m (down 33% from 2Q 2023). Profit margin: 35% (down from 42% in 2Q 2023). Revenue is expected to decline by 4.2% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 20%. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
New Risk • Sep 03New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 100% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 100% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (zł307.1m market cap, or US$79.2m).
New Risk • Jul 16New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 112% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 112% per year for the foreseeable future. High level of non-cash earnings (128% accrual ratio). Minor Risk Market cap is less than US$100m (zł283.8m market cap, or US$72.4m).
お知らせ • May 25Mabion S.A., Annual General Meeting, Jun 17, 2024Mabion S.A., Annual General Meeting, Jun 17, 2024.
Reported Earnings • May 19First quarter 2024 earnings released: EPS: zł1.06 (vs zł1.02 in 1Q 2023)First quarter 2024 results: EPS: zł1.06 (up from zł1.02 in 1Q 2023). Revenue: zł34.0m (down 14% from 1Q 2023). Net income: zł17.5m (up 6.5% from 1Q 2023). Profit margin: 52% (up from 42% in 1Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 91% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
分析記事 • Apr 24Mabion's (WSE:MAB) Shareholders May Want To Dig Deeper Than Statutory ProfitFollowing the solid earnings report from Mabion S.A. ( WSE:MAB ), the market responded by bidding up the stock price...
Price Target Changed • Apr 19Price target increased by 9.6% to zł16.17Up from zł14.75, the current price target is an average from 3 analysts. New target price is approximately in line with last closing price of zł17.00. Stock is down 9.0% over the past year. The company posted earnings per share of zł2.55 last year.
Reported Earnings • Apr 18Full year 2023 earnings released: EPS: zł2.55 (vs zł1.44 in FY 2022)Full year 2023 results: EPS: zł2.55 (up from zł1.44 in FY 2022). Revenue: zł151.7m (down 7.5% from FY 2022). Net income: zł41.3m (up 78% from FY 2022). Profit margin: 27% (up from 14% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 1.1% p.a. on average during the next 3 years, while revenues in the Biotechs industry in Europe are expected to grow by 18%. Over the last 3 years on average, earnings per share has increased by 103% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings.
New Risk • Feb 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 16% per year for the foreseeable future. High level of non-cash earnings (34% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (zł277.2m market cap, or US$68.7m).
お知らせ • Jan 12+ 3 more updatesMabion S.A. to Report Q3, 2024 Results on Nov 25, 2024Mabion S.A. announced that they will report Q3, 2024 results on Nov 25, 2024
分析記事 • Nov 28Mabion S.A. (WSE:MAB) Shares Fly 30% But Investors Aren't Buying For GrowthThe Mabion S.A. ( WSE:MAB ) share price has done very well over the last month, posting an excellent gain of 30%. While...
Valuation Update With 7 Day Price Move • Nov 27Investor sentiment improves as stock rises 22%After last week's 22% share price gain to zł21.88, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 25x in the Biotechs industry in Europe. Total returns to shareholders of 1.8% over the past three years.
Reported Earnings • Nov 17Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł29.6m (down 23% from 3Q 2022). Net income: zł10.9m (up zł15.9m from 3Q 2022). Profit margin: 37% (up from net loss in 3Q 2022). The move to profitability was driven by lower expenses. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 14Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł36.0m (down 18% from 2Q 2022). Net income: zł15.2m (up 198% from 2Q 2022). Profit margin: 42% (up from 12% in 2Q 2022). The increase in margin was driven by lower expenses. Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Biotechs industry in Europe.
お知らせ • Jun 13Mabion S.A., Annual General Meeting, Jun 13, 2023Mabion S.A., Annual General Meeting, Jun 13, 2023, at 14:00 Central European Standard Time.
分析記事 • Jun 02Industry Analysts Just Made A Huge Upgrade To Their Mabion S.A. (WSE:MAB) Revenue ForecastsMabion S.A. ( WSE:MAB ) shareholders will have a reason to smile today, with the analysts making substantial upgrades...
Major Estimate Revision • May 28Consensus revenue estimates decrease by 17%, EPS upgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from zł190.5m to zł159.0m. EPS estimate increased from zł0.52 to zł2.07 per share. Net income forecast to grow 42% next year vs 18% growth forecast for Biotechs industry in Poland. Consensus price target up from zł14.75 to zł15.35. Share price was steady at zł18.10 over the past week.
Price Target Changed • Apr 19Price target decreased by 9.2% to zł14.75Down from zł16.25, the current price target is an average from 2 analysts. New target price is 22% below last closing price of zł18.90. Stock is down 44% over the past year. The company is forecast to post earnings per share of zł1.57 for next year compared to zł0.12 last year.
お知らせ • Jan 26+ 2 more updatesMabion S.A. to Report First Half, 2023 Results on Sep 12, 2023Mabion S.A. announced that they will report first half, 2023 results on Sep 12, 2023
Major Estimate Revision • Dec 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from zł183.9m to zł164.9m. EPS estimate unchanged from zł1.57 per share at last update. Biotechs industry in Poland expected to see average net income growth of 1.6% next year. Consensus price target down from zł16.25 to zł15.75. Share price rose 5.1% to zł22.04 over the past week.
Price Target Changed • Nov 16Price target decreased to zł16.25Down from zł26.00, the current price target is an average from 2 analysts. New target price is 26% below last closing price of zł22.00. Stock is down 67% over the past year. The company is forecast to post earnings per share of zł1.57 for next year compared to zł0.12 last year.
Major Estimate Revision • Oct 06Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from zł275.0m to zł183.9m. EPS estimate unchanged from zł1.57 per share at last update. Biotechs industry in Poland expected to see average net income growth of 8.6% next year. Consensus price target down from zł26.00 to zł16.25. Share price was steady at zł19.86 over the past week.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to zł26.18, the stock trades at a trailing P/E ratio of 16x. Average forward P/E is 22x in the Biotechs industry in Poland. Total loss to shareholders of 65% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at zł12.27 per share.
分析記事 • Jul 09Does Mabion (WSE:MAB) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 15% share price gain to zł25.20, the stock trades at a trailing P/E ratio of 15.4x. Average forward P/E is 32x in the Biotechs industry in Poland. Total loss to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at zł11.29 per share.
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to zł21.60, the stock trades at a trailing P/E ratio of 13.2x. Average forward P/E is 31x in the Biotechs industry in Poland. Total loss to shareholders of 71% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at zł11.53 per share.
分析記事 • Jun 04Mabion (WSE:MAB) Is Posting Solid Earnings, But It Is Not All Good NewsSolid profit numbers didn't seem to be enough to please Mabion S.A.'s ( WSE:MAB ) shareholders. We think that they...
Price Target Changed • Apr 27Price target increased to zł68.50Up from zł47.30, the current price target is provided by 1 analyst. New target price is 145% above last closing price of zł28.00. Stock is down 57% over the past year. The company is forecast to post a net loss per share of zł3.67 next year compared to a net loss per share of zł4.06 last year.
Breakeven Date Change • Apr 27Forecast breakeven date moved forward to 2022The analyst covering Mabion previously expected the company to break even in 2023. New forecast suggests the company will make a profit of zł59.0m in 2022. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Buying Opportunity • Jan 24Now 33% undervalued after recent price dropOver the last 90 days, the stock is down 45%. The fair value is estimated to be zł59.41, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 157% per annum over the last 3 years. Earnings per share has grown by 16% per annum over the last 3 years.
分析記事 • Dec 22Is Mabion (WSE:MAB) Using Too Much Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Price Target Changed • Oct 12Price target increased to zł68.50Up from zł47.50, the current price target is an average from 2 analysts. New target price is 13% below last closing price of zł78.90. Stock is up 186% over the past year.
分析記事 • Sep 11Mabion S.A. (WSE:MAB) Shares Could Be 47% Below Their Intrinsic Value EstimateToday we'll do a simple run through of a valuation method used to estimate the attractiveness of Mabion S.A. ( WSE:MAB...
Major Estimate Revision • Jul 25Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast increased from zł8.00m to zł51.5m. EPS estimate unchanged from -zł3.67 at last update. Biotechs industry in Poland expected to see average net income decline 11% next year. Consensus price target up from zł27.30 to zł47.50. Share price rose 11% to zł64.00 over the past week.
お知らせ • Mar 04Mabion Biotech Signs Deal with Novavax on Covid-19 Vaccine Technology TransferMabion signed a deal with Novavax to transfer the manufacturing process and open the way for commercial-scale production of an antigen for a COVID-19 vaccine candidate, Mabion. The Master Service Agreement enables Mabion "with assistance of Novavax, to initiate activities required to transfer the manufacturing process and to establish the feasibility of commercial-scale manufacturing of antigen for Novavax's vaccine candidate" at Mabion's premises. Mabion expects that the transfer of the technology and its verification will be completed in first half 2021. The deal is effective through December 31, 2023.
分析記事 • Feb 24How Much Of Mabion S.A. (WSE:MAB) Do Institutions Own?The big shareholder groups in Mabion S.A. ( WSE:MAB ) have power over the company. Institutions often own shares in...
Is New 90 Day High Low • Feb 22New 90-day high: zł27.40The company is up 13% from its price of zł24.20 on 24 November 2020. The Polish market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is zł7.76 per share.
お知らせ • Jan 08+ 3 more updatesMabion S.A. to Report Q2, 2021 Results on Sep 16, 2021Mabion S.A. announced that they will report Q2, 2021 results on Sep 16, 2021
Is New 90 Day High Low • Dec 21New 90-day low: zł20.50The company is down 34% from its price of zł31.20 on 22 September 2020. The Polish market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 1.0% over the same period.
Is New 90 Day High Low • Nov 30New 90-day low: zł21.50The company is down 33% from its price of zł32.25 on 01 September 2020. The Polish market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 12% over the same period.
Is New 90 Day High Low • Oct 30New 90-day low: zł21.90The company is down 11% from its price of zł24.50 on 31 July 2020. The Polish market is down 15% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Biotechs industry, which is also down 11% over the same period.
お知らせ • Jun 16Mabion S.A. announced that it expects to receive PLN 1.563755 million in fundingMabion S.A. (WSE:MAB) announced a private placement of up to 1,907,281 ordinary U series bearer shares for minimum gross proceeds of PLN 190,728.10 and maximum of PLN 1,563,755.30 in May 2020. The transaction will include participation from new shareholders, as the shares issued will be in accordance of the exclusion of pre-emptive rights for existing shareholders.